- Trial phase
- Approved
- Time to market
- Already on the market. First FDA approval was December 2019; latest label expansion July 2026.
- Why 4/10
- Padcev is already FDA-approved and commercially launched with no pending regulatory decision; the last PDUFA (August 17, 2026) was resolved with early approval on July 10, 2026. The next potential catalyst is the EV-309 Phase 3 bladder-sparing readout, but it is still recruiting with no fixed date. As an approved drug at a diversified mega-cap pharma, impactScore is 4.
Watch for EV-309 (bladder-sparing) Phase 3 data readout, listed on Pfizer's 2026 pipeline catalyst page but still recruiting per ESMO 2026. Any positive readout could support another label expansion. Near-term, track quarterly sales growth trajectory as the July 2026 MIBC label expansion ramps.
Price Chart
Executive Summary
Padcev (enfortumab vedotin) is an FDA-approved antibody-drug conjugate targeting Nectin-4 for bladder cancer, co-developed by Astellas and Pfizer (Pfizer acquired Seagen in 2023). Originally approved in 2019, it received a major label expansion on July 10, 2026 for perioperative treatment of muscle-invasive bladder cancer regardless of cisplatin eligibility, and the European Commission expanded approval on October 23, 2026. Q3 2026 sales reached $720 million (23% YoY growth, beating consensus), helping drive Pfizer to raise full-year guidance. As an already-approved, commercially growing drug at a diversified mega-cap pharma with no imminent binary catalyst, the investment outlook is neutral.
How It Works
Padcev is an antibody-drug conjugate (ADC) that works like a guided missile. One part is an antibody that latches onto Nectin-4, a protein found on the surface of bladder cancer cells. Once attached, the drug releases a chemotherapy payload (MMAE) directly inside the cancer cell, disrupting its internal skeleton and killing it. This targeted approach aims to spare healthy cells.
Trial Status
Padcev is FDA-approved in multiple bladder cancer settings. The Phase 3 EV-302 trial (1L metastatic urothelial cancer) and EV-303/EV-304 trials (perioperative MIBC) have all reported positive results supporting approvals. The Phase 3 EV-309 trial (bladder-sparing approach) is currently recruiting.
The Two-Sided Case
Upcoming Catalysts
- EV-309 Phase 3 data readout for bladder-sparing treatment in MIBC (no fixed date; still recruiting per ESMO 2026)
- Continued commercial ramp from July 2026 MIBC label expansion
- Potential additional label expansions in earlier-stage bladder cancer settings
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report